Our team is disseminating the results of our work through manuscripts, abstracts, and presentations

• Can mind-altering prescription medicines be safe? Lessons from ketamine and esketamine; Richard C. Dart Clinical Toxicology, DOI: 10.1080/15563650.2024.2380773

https://doi.org/10.1080/15563650.2024.2380773

• Optimizing real-world benefit and risk of new psychedelic medications: the need for innovative postmarket surveillance. ; Joshua C. Black, Andrew A. Monte, Nabarun Dasgupta, Jennifer S. Jewell, Karilynn M. Rockhill, Richard A. Olson & Richard C. Dart : Nat. Mental Health

Optimizing real-world benefit and risk of new psychedelic medications: the need for innovative postmarket surveillance | Nature Mental Health

• Comparing Substance Use Consequences between Serotonergic Psychedelics, MDMA, and other Drugs of Abuse Among United States Adults with History of Psychiatric Illness. ; Black, J.C., Schow, N., Burkett, H.L. et al. : Int Journal of Mental Health & Addiction 2023 Sept 26.

https://doi.org/10.1007/s11469-023-01163-2

• Real-World Challenges of Psychedelic Therapies:  Lucid News, interview of Richard Dart by Floris Wolswijk

Real-World Challenges of Psychedelic Therapies - Lucid News